Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Immutep LimitedNASDAQ: IMMP

Accounts Payables · Q2 FY2026 · quarter ended Dec 2025

Accounts payables outflow grows to A$0

Q2 FY2026 accounts payables was A$0, compared with A$0 a year earlier.

Context

  • Accounts payables amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$0— QoQ
Last fiscal yearJun 2025
A$0— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

AUD · from the cash flow

Latest · FY2025
0 AUD
Year-over-year change
—

Accounts Payables vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Accounts payables amounts to 0.0% of revenue for IMMP, versus a peer median of 5.4%.
IMMP Competitors
Accounts Payables for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$11.66M USD+88.8%+10.3%5.4%
CADLCandel Therapeutics, Inc.LTM Mar 2026$1.99M USD+632.7%——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.59M USD-99.4%+70.5%—
EDITEditas Medicine, Inc.LTM Mar 2026$1.13M USD+32.3%—2.9%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$824K USD-164.2%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$752K USD+384.8%—13.1%
MREOMereo BioPharma Group plcLTM Mar 2026$456.35K USD+226.0%—91.3%
CABACabaletta Bio, Inc.LTM Mar 2026$310K USD-132.7%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$232K USD-67.8%——
IMMPImmutep LimitedFY2025A$0 AUD——0.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€0 EUR——0.0%
Peer median (excluding IMMP) —+32.3%+40.4%5.4%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Depreciation & Amortization2.07M2.06M2.06M2.26M2.39M
Deferred Income Tax(7.29M)0(4.99M)00
Stock-Based Compensation1.7M1.49M2M1.8M1.16M
Change in Working Capital(1.99M)(1.56M)764.6K3.46M(8.54M)
Accounts Receivables(2.83M)(2.25M)(1.61M)601.77K(2.52M)
Inventory0813.92K000
Accounts Payables1.38M1.44M3.27M00
Other Working Capital(543.42K)(1.56M)(900.11K)2.86M(6.02M)
Other Non-Cash Items17.77M(8.04K)4.17M379.87K4.37M
Operating Cash Flow(17.64M)(30.23M)(35.88M)(34.82M)(62.05M)
Capital Expenditures(15.6K)(22.91K)(47K)(932.37K)(45.77K)
Acquisitions (Net)00000
Purchases of Investments000(20.09M)0
Sales of Investments00000
Other Investing Activities0016K(903.15K)(38.49M)
Investing Cash Flow(15.6K)(22.91K)(31K)(21.02M)(38.53M)
Debt Repayment(214.38K)(222.54K)(211.97K)(226.49K)(270.67K)
Common Stock Issued43.31M52.98M80.08M100.24M(164.79K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.59M(2.43M)(3.83M)(4.83M)(254.46K)
Financing Cash Flow52.68M50.33M76.04M95.18M(525.12K)
Effect of Forex Changes(752.84K)(671.04K)3.3M(967.73K)6.73M
Net Change in Cash34.27M19.4M43.42M38.37M(94.38M)
Free Cash Flow(17.66M)(30.25M)(35.93M)(35.75M)(62.1M)

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.